This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US

Hurry! $500 Savings Ends In:

  • 00
  • 00
  • 00
  • 00
December 4 - 8, 2022
Marriott Marquis San DiegoDelivered as a Hybrid Event

Liaoyuan Hu, Ph.D.
CEO at ReCentrics Bio


Dr. Liaoyuan Hu is currently the CEO and cofounder of ReCentrics Bio., a startup company focused on developing therapeutic antibodies against GPCR targets for the treatment of diseases with unmet medical need. Before founding ReCentrics, Liaoyuan worked as a Scientific Director, Head of in vitro Pharmacology at Amgen Asia R&D Center, where he directed the effort to build various technology platforms to support Amgen innovative drug discovery.  Prior to joining Amgen, Liaoyuan served in a variety of discovery-focused roles at Eli Lilly China R&D Center and Lexicon Pharmaceutics, and was responsible for target validation, early candidate identification and characterization for drug discovery programs.  Liaoyuan earned his Ph.D degree from University of Texas Medical Branch at Galveston and did his postdoctoral training on GPCR signaling transduction in Dr. Lefkowitz’s lab at Duke University.

Agenda Sessions

  • Function-based Screening for Antibody Antagonists and Agonists Against Human Apelin